MPX International Corporation (MPXOF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MPX International Corporation (MPXOF) with AI Score 68/100 (Buy). MPX International Corporation focuses on the medical and adult-use cannabis markets in Canada and Switzerland. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026MPX International Corporation (MPXOF) Healthcare & Pipeline Overview
MPX International Corporation operates in the cannabis industry, focusing on producing and distributing cannabis flowers, extracts, and derivatives for medical and adult-use markets in Canada and Switzerland. With a negative P/E ratio and high gross margin, the company navigates a competitive landscape with its Strain Rec and Salus BioPharma brands.
Investment Thesis
MPX International Corporation presents a speculative investment thesis, given its current financial metrics and market positioning. The company's negative P/E ratio of -0.03 and a profit margin of -369.4% indicate significant challenges in achieving profitability. However, its gross margin of 62.9% suggests potential in its core operations if costs can be managed effectively. Key growth catalysts include expansion within the Canadian and Swiss cannabis markets and potential regulatory changes that could broaden market access. The company's success hinges on its ability to scale operations, control costs, and differentiate its products in a competitive landscape. Investors should closely monitor the company's financial performance and strategic initiatives to assess its long-term viability.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's small size and potential volatility.
- P/E Ratio of -0.03 indicates the company is currently not profitable.
- Profit Margin of -369.4% highlights significant challenges in achieving profitability.
- Gross Margin of 62.9% suggests potential in core operations if costs are managed effectively.
- Beta of -1.09 indicates the stock price moves in the opposite direction of the market.
Competitors & Peers
Strengths
- Established presence in both Canadian and Swiss markets.
- Diversified product portfolio including flowers, extracts, and derivatives.
- Brand recognition through Strain Rec and Salus BioPharma brands.
Weaknesses
- Negative P/E ratio and low profitability.
- Limited market share compared to larger competitors.
- Dependence on regulatory approvals and changes.
Catalysts
- Upcoming: Potential regulatory changes in Canada and Switzerland that could expand market access.
- Ongoing: Expansion of product offerings under the Strain Rec and Salus BioPharma brands.
- Ongoing: Strategic partnerships and acquisitions to enhance distribution and market share.
Risks
- Potential: Intense competition from established players in the cannabis industry.
- Potential: Fluctuations in cannabis prices and market demand.
- Ongoing: Dependence on regulatory approvals and changes.
- Ongoing: Negative P/E ratio and low profitability.
Growth Opportunities
- Expansion in the Canadian Market: The Canadian cannabis market is projected to reach $4 billion by 2027, presenting a significant growth opportunity for MPX International. The company can leverage its existing infrastructure and brand recognition to expand its market share by introducing new products, targeting specific consumer segments, and optimizing its distribution network. Success in this market requires adapting to evolving regulations and consumer preferences.
- Penetration of the Swiss Market: The Swiss cannabis market, while smaller than Canada's, offers unique opportunities due to its regulatory environment and consumer base. MPX International can capitalize on this by tailoring its product offerings to meet local demand, establishing strategic partnerships with local distributors, and navigating the regulatory landscape effectively. The Swiss cannabis market is expected to grow steadily, driven by increasing acceptance and evolving regulations.
- Development of New Cannabis Derivatives: MPX International can drive growth by investing in the research and development of new cannabis derivatives, such as edibles, topicals, and concentrates. These products cater to a broader range of consumer preferences and offer higher profit margins compared to traditional cannabis flowers. The market for cannabis derivatives is expanding rapidly, driven by innovation and changing consumer tastes. Successful product development requires a deep understanding of consumer needs and regulatory requirements.
- Strategic Partnerships and Acquisitions: MPX International can accelerate its growth by pursuing strategic partnerships and acquisitions with other cannabis companies. These partnerships can provide access to new markets, technologies, and distribution channels. Acquisitions can consolidate market share and create synergies that improve operational efficiency. The cannabis industry is consolidating rapidly, with larger players acquiring smaller companies to expand their reach and capabilities.
- Focus on Medical Cannabis Market: MPX International can strengthen its position by focusing on the medical cannabis market, which offers higher margins and greater regulatory stability compared to the recreational market. The company can develop specialized products for specific medical conditions, establish relationships with healthcare professionals, and conduct clinical trials to validate the efficacy of its products. The medical cannabis market is growing steadily, driven by increasing awareness of the therapeutic benefits of cannabis.
Opportunities
- Expansion into new geographic markets.
- Development of new cannabis-based products.
- Strategic partnerships and acquisitions.
Threats
- Intense competition from established players.
- Changing regulatory landscape.
- Fluctuations in cannabis prices.
Competitive Advantages
- Brand recognition through Strain Rec and Salus BioPharma brands.
- Established presence in both the Canadian and Swiss cannabis markets.
- Diversified product portfolio including flowers, extracts, and derivatives.
About MPXOF
Founded in 2015 and headquartered in Toronto, Canada, MPX International Corporation is a cannabis company focused on the medical and adult-use markets in Canada and Switzerland. The company's core business revolves around the production and distribution of a range of cannabis products, including cannabis flowers, cannabis extracts, and cannabis derivatives. These products are marketed under the company's two primary brands: Strain Rec and Salus BioPharma. Strain Rec focuses on the recreational cannabis market, while Salus BioPharma caters to the medical cannabis sector. MPX International aims to establish a strong presence in both the Canadian and Swiss cannabis markets. The company navigates a complex regulatory environment while focusing on product innovation and market expansion. MPX International continues to adapt its strategies to capitalize on emerging opportunities in the evolving cannabis industry.
What They Do
- Produces cannabis flowers for recreational and medical use.
- Manufactures cannabis extracts, including oils and concentrates.
- Develops cannabis derivatives such as edibles and topicals.
- Distributes cannabis products under the Strain Rec brand for recreational use.
- Distributes cannabis products under the Salus BioPharma brand for medical use.
- Operates in the Canadian cannabis market.
- Operates in the Swiss cannabis market.
Business Model
- MPX International generates revenue through the sale of cannabis flowers, extracts, and derivatives.
- The company operates under two primary brands: Strain Rec for recreational cannabis and Salus BioPharma for medical cannabis.
- MPX International distributes its products through various channels, including retail stores and online platforms.
Industry Context
MPX International operates within the rapidly evolving cannabis industry, which is experiencing significant growth and regulatory changes across North America and Europe. The Canadian cannabis market, where MPX has a presence, is characterized by increasing competition and evolving consumer preferences. Similarly, the Swiss cannabis market, while smaller, presents unique opportunities due to its regulatory framework and consumer base. The industry is marked by intense competition from both established players and new entrants, all vying for market share. Companies must navigate complex regulatory landscapes, adapt to changing consumer trends, and invest in product innovation to succeed.
Key Customers
- Adult consumers in Canada seeking recreational cannabis products.
- Patients in Canada and Switzerland requiring medical cannabis for therapeutic purposes.
- Retailers and distributors who sell MPX International's products to end consumers.
Financials
Chart & Info
MPX International Corporation (MPXOF) stock price: Price data unavailable
Latest News
No recent news available for MPXOF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MPXOF.
Price Targets
Wall Street price target analysis for MPXOF.
MoonshotScore
What does this score mean?
The MoonshotScore rates MPXOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William Scott Boyes
CEO
William Scott Boyes serves as the CEO of MPX International Corporation. His background includes extensive experience in the cannabis industry, with a focus on strategic planning, business development, and regulatory compliance. He has held various leadership positions in cannabis companies, contributing to their growth and expansion. Boyes' expertise spans across cultivation, processing, and distribution within the cannabis sector. He is known for his ability to navigate complex regulatory environments and drive innovation in product development.
Track Record: Under William Scott Boyes' leadership, MPX International has focused on expanding its presence in the Canadian and Swiss cannabis markets. Key milestones include the launch of new product lines under the Strain Rec and Salus BioPharma brands and the establishment of strategic partnerships to enhance distribution. Boyes has also overseen efforts to improve operational efficiency and reduce costs. His strategic decisions have aimed to position MPX International for long-term growth and profitability in the evolving cannabis industry.
MPXOF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MPX International Corporation may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading volume can be thin. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ, due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Thin trading volume and potential price volatility.
- Higher risk of fraud or manipulation compared to major exchanges.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any news or reports of fraud or misconduct.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 2015.
- Focuses on the medical and adult-use cannabis markets in Canada and Switzerland.
- Produces and distributes cannabis products under the Strain Rec and Salus BioPharma brands.
MPXOF Healthcare Stock FAQ
What does MPX International Corporation do?
MPX International Corporation is a cannabis company focused on the medical and adult-use markets in Canada and Switzerland. It produces and distributes cannabis flowers, extracts, and derivatives under the Strain Rec and Salus BioPharma brands. Strain Rec caters to the recreational market, while Salus BioPharma focuses on medical cannabis. The company's operations include cultivation, processing, and distribution, with a goal of establishing a strong presence in both the Canadian and Swiss cannabis markets.
What do analysts say about MPXOF stock?
There is currently no available analyst coverage for MPXOF stock. Given the company's OTC listing and small market capitalization, it may not be actively tracked by major investment firms. Investors should conduct their own thorough research and due diligence before considering an investment in MPXOF. Key valuation metrics to consider include revenue growth, gross margin, and cash flow. Growth considerations include expansion in the Canadian and Swiss markets and potential regulatory changes.
What are the main risks for MPXOF?
The main risks for MPXOF include intense competition in the cannabis industry, fluctuations in cannabis prices, and dependence on regulatory approvals. The company's negative P/E ratio and low profitability also pose significant risks. Additionally, as an OTC-listed stock, MPXOF faces risks related to limited liquidity, financial disclosure, and regulatory oversight. Investors should carefully consider these risks before investing in MPXOF.
What are the key factors to evaluate for MPXOF?
MPX International Corporation (MPXOF) currently holds an AI score of 68/100, indicating moderate score. Key strength: Established presence in both Canadian and Swiss markets.. Primary risk to monitor: Potential: Intense competition from established players in the cannabis industry.. This is not financial advice.
How frequently does MPXOF data refresh on this page?
MPXOF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MPXOF's recent stock price performance?
Recent price movement in MPX International Corporation (MPXOF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in both Canadian and Swiss markets.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MPXOF overvalued or undervalued right now?
Determining whether MPX International Corporation (MPXOF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MPXOF?
Before investing in MPX International Corporation (MPXOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for MPX International Corporation.
- OTC stocks carry higher risks than exchange-listed stocks.